Top Alliances In April 2019
POTENTIAL DEAL VALUE IS THE SUM OF UP-FRONT FEES PLUS PRE- AND POST-COMMERCIALIZATION MONEY.Medtrack; Strategic Transactions | Pharma Intelligence, 2019
Deals In Depth: April 2019
Alnylam and Regeneron will work on RNAi therapies for ocular, CNS, and liver disease indications in a $1.15bn alliance. Novartis paid $310m up front for IFM Tre, which focuses on abnormal NLRP3 inflammasome activation. Biopharma financing was down in April compared with the previous month, but device funding increased.